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A B S T R A C T 
Human growth and development, starting from conception, are characterized by a progressive 
increase in body and organ dimensions, as well as specific functional maturity, under the influence 
of genetic as well as environmental and epigenetic determinants. Beyond a possible normal familial 
trait, increased fetal growth resulting in a large for gestational age newborn, isolated macrosomia or 
that associated with congenital malformation, can be attributable to both maternal metabolic and 
genetic pathology. Overgrowth syndromes are a heterogeneous group of diseases characterized by 
excessive tissue development often concomitant to neurodevelopmental involvement. Recently, an 
increased risk of fetal overgrowth with Assisted Reproductive Technology has been reported. Thus, 
in pediatric practice, it is fundamental to monitor any patient who presents with increased growth 
parameters, variable malformations, neurodevelopmental delay, and distinctive features from birth, 
aiming to ensure as adequate a medical management as possible, and for some of the disorders, 
strict tumor monitoring is also necessary.   
 
© EuroMediterranean Biomedical Journal  2020 
1. Introduction 
Conventionally gestation is the period of time between conception and 
birth when a baby grows and develops inside the mother's womb. Since, 
apart from selected cases as in Assisted Reproductive Technology (ART), 
it is impossible to know exactly when conception occurs, gestational age 
is measured in weeks from the first day of the mother's last menstrual 
cycle to the current date. Thus, although a normal pregnancy lasts for 
about 280 days or 40 weeks, the corresponding period of real embryofetal 
development lasts 266 days or 38 weeks. A preterm or premature baby is 
delivered before 37 weeks of pregnancy. Extremely preterm infants are 
born from 23 to 28 weeks of gestation. Moderately preterm infants are 
born between 29 and 33 weeks, and late preterm from 34 to 36+6 weeks. 
Thus, to monitor both anthropometric and functional neurodevelopment a 
corrected age for prematurity must be considered for at least the first two 
years of life. During all three trimesters of pregnancy normal fetal growth 
is a critical component of a healthy pregnancy and influences the long-
term outcomes of the offspring (1). To monitor intrauterine growth, charts 
derived from anthropometric studies conducted on the reference 
population only should be adopted (2,3).  
 
Using a statistical approach, any neonate weighing >90th percentile for 
gestational age is considered large for gestational age (LGA). 
Nevertheless, to better identify the more at-risk conditions some 
researchers prefer to use the two standard deviations from the mean 
accounting for about 95.4% of the population. To define the most severely 
affected subjects, similarly to other anthropometric-clinical correlations, 
three standard deviations, accounting for about 99.7% of the population, 
are generally used (4). 
A strict postnatal clinical and instrumental follow-up should be planned in 
case of overgrowth, especially oriented towards early identification of 
concomitant neurosensorial involvement. Nowadays, hearing screening 
using the Otoacoustic Emissions Test (OAEs), and the examination of the 
red reflex of the eyes are routinely performed in every newborn, relying 
on developmental surveillance for early impairment identification. 
Nevertheless, is important to consider that, apart from the cardiac 
localized overgrowth of fibrous and elastic tissues (endocardial 
fibroelastosis), present in 3-Methylglutaconic aciduria type 2 (Barth 
Syndrome, MIM# 302060), the generalized overgrowth syndromes are not 
identified through expanded neonatal metabolic screening (5).  
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2. Large for gestational age and macrosomia 
The term Large for gestational age (LGA) defines a newborn whose 
birthweight is over the 90th percentile, referring to growth charts built on 
the reference population. Thus, around 9.9% of newborns are expected to 
be LGA. The term macrosomia is used to define a term neonate 
birthweight > 4,000 g, or > 4,500 irrespective of gestational age (6). 
Nevertheless, it might be more appropriate to define macrosomia as a 
value 2 standard deviations (SD) above the mean adopting the reference 
population growth charts. 
It is important to differentiate a generalized overgrowth from macrosomia. 
Infants with generalized overgrowth are frequently described as “long and 
thin” with relatively increased weight secondary to their presentation of 
increased birth length.  
The most frequent pathology responsible for LGA and macrosomia is 
maternal diabetes. 
In pregnancy two types of diabetes can occur; a pregestational diabetes 
related to women who already have insulin-dependent diabetes and 
become pregnant, and gestational diabetes affecting a mother who does 
not have diabetes before becoming pregnant, but develops a resistance to 
insulin because of the hormones of pregnancy (estrogen, cortisol, human 
placental lactogen). The great majority of investigators find a two- to 
threefold increase in malformations in infants of insulin-dependent 
diabetic mothers compared to infants of gestational diabetics. When 
diabetes is controlled by diet or oral hypoglycemic agents, the increased 
risk of malformation is not reported. 
Although both types of diabetes can lead to LGA and macrosomia 
conditions, pregestational diabetes can exert toxic effects on the embryo, 
through hyperglycemia-induced teratogenesis affecting the development 
of several organsbefore the seventh gestational week. The most frequent 
malformations reported include; central nervous system (CNS) 
(anencephaly, spina bifida, holoprosencephaly, microcephaly), 
cardiovascular system (single umbilical artery, transposition of the great 
vessels, ventricular septal defects, atrial septal defects, coarctation of the 
aorta), gastrointestinal system (duodenal atresia, small left colon 
syndrome, anorectal atresia,), renal system (renal agenesis, ureteric 
abnormalities), skeletal system (limb defects, caudal regression 
syndrome/syrenomelia, isolated sacral agenesis) (7,8). 
Macrosomia is associated with increased risks of intra-uterine death and 
stillbirth.At birth, maternal complications have been reported as prolonged 
labor, and with vaginal delivery uterine rupture, perineal trauma and 
postpartum hemorrhage. Newborns with macrosomia show a higher risk 
of shoulder dystocia, clavicle fracture and brachial plexus palsy. 
Admission to neonatal intensive care unit (NICU) can be related to 
cardiorespiratory, maladaptation or asphyxia, and polycythemia along 
with prolonged hypoglycemia that can lead to severe neurological 
consequences, when not identified early and treated (9,10). 
Frozen embryo transfer, one of the newest types of ART, in relation to a 
reduced risk of ovarian hyperstimulation syndrome, multiple pregnancy, 
and low birth weight in singleton has become a technique of choice versus 
fresh embryo transfer. Nevertheless, the frozen versus the fresh type has 
been correlated with an increased risk of LGA (11). 
A long term effect of being LGA is an increased risk of obesity and/or 
insulin-resistance (12,13).  
Nevertheless, a recent study showed that the associations between birth 
weight and overweight/obesity at 15–20 years of age were modest, 
whereas the influence of body mass index (BMI) at 2–4 and 5–7 years on 
overweight/obesity at 15–20 years was moderate to strong (14). 
3. Overgrowth 
Samples Somatic growth is dependent on an increase in cell size, cell 
number or both. Overgrowth can be generalized, involving the whole 
body and accompanied by other clinical signs, defining a syndrome, or 
segmental, e.g. hemimegaloencephaly. It is important to distinguish at 
birth between a syndrome of generalized overgrowth from macrosomia 
“sensu strictu”, as previously defined.  
Nowadays we are seeing a continuous expansion in the genes responsible 
for clinical conditions characterized by overgrowth, and the two terms are 
not always well distinguished. Thus, searching for “overgrowth” in Online 
Mendelian in Men (OMIM), we obtained 221 entries, and searching for 
“macrosomia” 44 entries (15). Some chromosomal conditions, often 
associated with generalized overgrowth, have been diagnosed by 
chromosome microarray (16,17).  
Overgrowth syndromes comprise a heterogeneous group of diseases that 
are characterized by excessive tissue development, share several clinical 
signs and are associated with various degrees of developmental 
delay/intellectual disabilities as well as neurobehavioral disorders (Table 
1). 
Underlying mechanisms responsible for overgrowth have been recently 
defined.  
Some of these syndromes may be associated with dysfunction in the 
receptor tyrosine kinase (RTK)/PI3K/AKT pathway, which results in an 
increased expression of the insulin receptor. 
Other reported mechanisms are; epigenetic regulator genes, transcription 
factors, mutations of the gene encoding the endoribonuclease, 
channelopathies and disruption of extracellular signaling (16). 
Interestingly, growth pattern can be characterized in Cantu, Costello, 
Pallister Killian, and Perlman syndromes by a postnatal slowing (18).  
In Costello syndrome a postnatal failure to thrive and growth deficiency 
are often reported too (19).  
In Pallister Killian only up to 40% of patients maintain increased growth 
parameters, thus most of them show a postnatal progressive reduction to 
the lower centiles (20). 
Neurofibromatosis type 1 (NF1) is characterized by growth retardation 
and short stature. Nevertheless, overgrowth is part of the phenotypic 
spectrum in patients with the common 1.4/1.2 Mb NF1 microdeletions. 
Thus, the chromosomal region comprised by the microdeletions should 
contain a gene whose haploinsufficiency causes overgrowth which is most 
evident in preschool children aged 2-6 years (21,22). 
Overgrowth syndromes are frequently associated with an increased risk of 
cancer, specifically embryonic tumors in childhood and carcinomas in 
adulthood. An increased risk of neoplasia is present in Beckwith 
Wiedemann, Neurofibromatosis Type 1 (NF1), Sotos, Proteus, Perlman, 
BW syndrome (BWS), Costello, Simpson-Golabi-Behmel, Weaver and 
PTEN hamartoma tumor syndromes (23). 
Embryonic types of cancer due to the overexpressing of IGF2, have been 
well described in BWS withup to 10% of children developing a cancer; 
Wilms tumor, adrenocortical carcinomas, carcinomas, hepatoblastomas. 
neuroblastoma and rhabdomyosarcoma. The individual risk is related to 
the genetic basis and is higher, up to 26%, in the hypermethylation group, 
in comparison to KCNQ1OT1:TSS-DMR (IC2) subgroup (2.6%) (24). 
In NF1, the most frequent tumors are neurofibromas with plexiform type 
occurring in about 50% of patients.  
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The optic nerve gliomas affect about 10-15% of patients, and women with 
NF1 have a 3.5-fold increased risk of developing breast cancer (25,26). 
In Perlman syndrome there is an increased risk of developing a Wilms 
tumor which has been documented in 64% of patients (27).  
In Simpson-Golabi-Behmel, a lower, in comparison to previous reports, 
prevalence of Wilms tumor and leukemia has been reported (28). 
In Costello syndrome a significant increased risk, up to 15%, of 
developing a neuroblastoma, transitional cell carcinoma of the bladder and 
rhabdomyosarcoma is described (29)  
Sotos syndrome, in comparison to other overgrowth syndromes shows a 
lower risk of tumor, at around 3%, however, it is still present, and 
includes neuroblastoma, retinoblastoma, small cell lung cancer, 
sacrococcygeal teratoma and presacral ganglioma.  
It is important to remember that is not unusual for children with a milder 
form of Sotos syndrome to eventually be given a diagnosis after several 
years of investigations for a variable degree of developmental delay (30). 
 
 
Table 1. Main overgrowth syndromes 
4. Epigenetic determinants 
Genomic imprinting is an epigenetic phenomenon, involving around 4100 
imprinted genes in humans, that leads to parent-specific differential 
expression of a subset of mammalian genes.  
The expression of every imprinting domain, formed from most imprinted 
genes, is regulated by imprinting control regions (ICRs). ICRs are 
identical to differentially methylated regions (DMRs), which are 
characterized by DNA methylation on one of the two parental alleles, 
either maternally methylated DMRs or paternally methylated DMRs. 
There are two classes of imprinted DMRs, gametic DMRs and somatic 
DMRs.  
Gametic DMRs acquire DNA methylation during gametogenesis, and the 
methylation is maintained from zygote to somatic cells during all 
developmental stages. Most gametic DMRs are identical to ICRs. 
Methylations of somatic DMRs are established during early 
embryogenesis after fertilization under the control of nearby ICRs. 
Epigenetic abnormalities responsible for an aberrant expression of 
imprinted genes mostly include histone modification, chromatin 
modelling and aberrant hypomethylation or hypermethylation at ICRs.  
Epigenetic regulator genes have been identified for Sotos, Weaver, 
Cohen-Gibson and Perlman syndromes (16). 
 
 
In embryos conceived by ART, especially through in vitro fertilization 
(IVF) and intracytoplasmic sperm injection (ICSI), an increased risk of 
imprinting disorders, such as BWS and Angelman syndrome, has been 
reported. The causative alteration for most of ART-related BWS is loss of 
methylation (LOM) at KvDMR1 (KvDMR1-LOM).  
Thus, a closer follow-up is necessary in case of ART for early 
identification of developmental anomalies (31, 32). 
5. Practical clinical and diagnostic considerations 
Early clinical identification of the specific overgrowth syndrome can be 
difficult for the clinician since phenotypes often overlap with patients 
exhibiting similar facial findings. In the first months of life, suspected 
developmental delay, generally associated with a generalized hypotonia of 
central origin, does not always allow for the identification of a developing 
cognitive impairment or the presence of autistic features. Thus, from 6-8 
months of age (corrected age for prematurity), applying standardized 
instruments for developmental assessment, the clinician should define the 
patient’s developmental quotient (mental age/chronological age). A 
normal development can orientate the diagnosis towards a familial type or 
endocrine conditions (hyperthyroidism, growth hormone-secreting 
adenoma, congenital adrenal hyperplasia, familial glucocorticoid 
deficiency, aromatase deficiency) (32). 
As a general rule, a clinician approaching an infant with suspected 
overgrowth syndrome should first rely on his own clinical acumen using 
the so-called “diagnostic handles” to identify a recognizable facial gestalt 
or specific pattern of malformations. Thus, an accurate clinical and 
instrumental diagnosis, including brain imaging and neurophysiological 
investigations, can allow the clinician to limit the number of genes to be 
analyzed in gene panels, reducing the number of results including variants 
of uncertain significance (VUS). The widespread adoption of exome 
sequencing and gene panels (16) has made it possible to significantly 
increase the diagnosis rate of overgrowth syndromes, which was around 
50%, 10 years ago (33). 
6. Conclusions 
Clinicians should attempt to define the diagnosis in a child with an 
overgrowth syndrome as early as possible. A multidisciplinary diagnostic 
and therapeutic team with pediatric leadership and including clinician 
geneticist, molecular biologist, pediatric neurologist, neurodevelopmental 
pediatrician, child neuropsychiatrist, ophthalmologist, audiologist and 
rehabilitation staff, should develop an individualized plan of 
developmental surveillance, rapid interventions in case of complications 
and strict monitoring in relation to the frequently increased tumor risk 
(34).  
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